Therefore, the in vitro studies on cellular uptake and cytotoxicity (Fig. 6C) indicate that these NPs are effective in delivering DTX to HER2-positive breast cancer cells, offering a promising approach for treating cancers characterized by elevated HER2 levels [87]. Here, ERBB2 is linked to cancer.